← All trials
NCT05790213
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2023
- Primary completion
- Apr 1, 2026
- Completion date
- Apr 1, 2028
- First posted
- Mar 30, 2023
- Last posted
- Aug 23, 2023
- Enrollment
- 57
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CincinnatiLead sponsor
- University of CincinnatiOverall official - principal investigator
- University of CincinnatiReponsible party - principal investigator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.